Federal Clinical Guidelines on Rendering Help to Children with Hemolytic Uremic Syndrome
https://doi.org/10.15690/pf.v12i4.1427
Abstract
The hemolytic uremic syndrome (HUS) is a serious therapeutic problem in pediatrics and pediatric nephrology. HUS is one of the leading causes of acute renal failure with the potential of transforming into terminal chronic renal failure at various periods from the disease onset. The typical form of HUS with a diarrheal prodrome associated with Shiga toxin (STEC) is the most common form. Despite this fact, it requires careful confirmation of infectious etiology to exclude atypical HUS and HUS associated with pneumococcal infection in time. In respect of STEC-HUS it is recommended to conduct adequate symptomatic therapy with a timely dialysis connection if needed. The prognosis here will depend on the anuretic period duration and on the related central nervous system injuries. Atypical HUS is often based on genetic mutations leading to the complement cascade disfunction with uncontrolled activation of the alternative pathway. The overall prognosis for this prone to recurrence form is unfavourable, however, it is recommended to conduct aeculizumabum treatment which will block the terminal components of the complement cascade.
About the Authors
A. N. Tsygin
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
T. V. Vashurina
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
T. V. Margieva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
P. V. Ananyin
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
A. M. Mazo
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
A. A. Pushkov
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
K. V. Savostianov
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Scheiring J., Andreoli S. P., Zimmerhackl L. B. Treatment and outcome of Shiga-toxin-associated haemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008; 23: 1749–60.
2. Taylor M. Enterohaemorrhagic Escherichia coli and Shigella dyseteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol. 2008; 23: 1425–31.
3. Ariceta G., Besbas N., Johnson S., Karpman D. et al. Guideline for the investigation and initial therapy of diarrhea-negative haemolytic uremic syndrome. Pediatr Nephrol. 2009; 24: 687–696.
4. Geraghty M. T., Perlman E. J., Martin L. S., Hayflick S. J., Casella J. F., Rosenblatt D. S., Valle D. Cobalamin C defect associated with hemolytic-uremic syndrome. J Pediatr. 1992; 120: 934–7.
5. Noris M., Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16: 1035–50.
6. Луара Ш. Гемолитико-уремический синдром. В кн.: Детская нефрология. Практическое руководство. Под ред. Э. Лойманна, А. Н. Цыгина, А. А. Саркисяна. М.: Литтерра. 2010. 400 с.
7. Шпикалова И. Ю., Панкратенко Т. Е., Эмирова Х. М., Зверев Д. В., Толстова Е. М. Поражение ЦНС у больных с Шигатоксин ассоциированным гемолитико-уремическим синдромом (STEC-ГУС): современные аспекты патогенеза, клиники и стратегии лечения. Обзор литературы. Нефрология и диализ. 2014; 16 (3): 328–338.
8. Oakes R. S., Kirkham J. K., Nelson R. D., Siegler R. L. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal haemolytic uremic syndrome. Pediatr Nephrol. 2008; 23: 1303–8.
9. Bresin E., Daina E., Noris M., Castelletti F., Stefanov R., Hill P., Goodship T. H., Remuzzi G. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006; 1: 88–99.
10. Ariceta G., Arrizabalaga B., Aguirre M., Morteruel E., Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis. 2012; 59: 707–10.
11. Каган М. Ю. Гемолитико-уремический синдром, ассоциированный с пневмококковой инфекцией. Обзор литературы. Нефрология и диализ. 2013; 15 (2): 116–119.
12. Copelovitch L., Kaplan B. S. Streptococcus pneumoniae-associated haemolytic uremic syndrome. Pediatr Nephrol. 2008; 23: 1951–6.
13. Loirat C., Noris M., Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008; 23: 1957–72.
14. Noris M., Remuzzi G. Atypical-hemolytic uremic syndrome. N Engl J Med. 2009; 361: 1676–87.
15. Legendre C. M., Licht C., Muus P., Greenbaum L. A., Babu S., Bedro sian C., Bingham C., Cohen D. J., Delmas Y., Douglas K., Eitner F., Feldkamp T., Fouque D., Furman R. R., Gaber O., Herthe lius M., Hourmant M., Karpman D., Lebranchu Y., Mariat C., Menne J., Moulin B., Nurnberger J., Ogawa M., Remuzzi G., Richard T., Sberro-Soussan R., Severino B., Sheerin N. S., Trivelli A., Zimmerhackl L. B., Goodship T., Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368: 2169–81.
16. Резолюция экспертного совета по оптимизации подходов к терапии атипичного гемолитико-уремического синдрома по итогам заседания 18 апреля 2014 г. Нефрология и диализ. 2014; 16 (2): 304–306.
17. Fakhouri F., Fremeaux-Bacchi V., Loirat C. Atypical hemolytic uremic syndrome: From the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013; 24: 492–5.
18. Loirat C., Fakhouri F., Ariceta G., Besbas N. et al. An international consensus approach to the management of atypical haemolytic uremic syndrome in children. Pediatr Nephrol. 2015; Published online: 11 April 2015.
19. Dragon-Durey M. A., Loirat C., Cloarec S., Macher M. A., Blouin J., Nivet H., Weiss L., Fridman W. H., Fremeaux-Bacchi V. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16: 555–63.
20. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., Piras R., Donadelli R., Maranta R., van der Meer I., Conway E. M., Zipfel P. F., Goodship T. H., Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5: 1844–59.
21. Davin J. C., Strain L., Goodship T. H. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol. 2008; 23: 1517–21.
22. Krid S., Roumenina L. T., Beury D., Charbit M., Boyer O., Fremeaux-Bacchi V., Niaudet P. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012; 12: 1938–44.
23. Weitz M., Amon O., Bassler D., Koenigsrainer A., Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011; 26: 1325–9.
24. Saland J. M., Emre S. H., Shneider B. L., Benchimol C., Ames S., Bromberg J. S., Remuzzi G., Strain L., Goodship T. H. Favorable longterm outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant. 2006; 6: 1948–52.
Review
For citations:
Tsygin A.N., Vashurina T.V., Margieva T.V., Ananyin P.V., Mazo A.M., Pushkov A.A., Savostianov K.V. Federal Clinical Guidelines on Rendering Help to Children with Hemolytic Uremic Syndrome. Pediatric pharmacology. 2015;12(4):447-455. (In Russ.) https://doi.org/10.15690/pf.v12i4.1427
Views:
21492
Email this article 